Table 1 Patients characteristics

Total number, n (%)

144 (38.3)

232 (61.7)

87 (33.6)

172 (66.4)

Age (years)

 Mean ± SD (range)

64.7 ± 9.3 (37–82)

60.8 ± 14.7 (18–89)

62.9 ± 10.4 (39–86)

59.3 ± 15.2 (22–85)

Gender, n (%)

 Male

92 (63.9)

101 (43.5)

53 (60.9)

99 (57.6)

 Female

52 (36.1)

131 (56.5)

34 (39.1)

73 (42.4)

Tumor location, n (%)

 iCCA

6 (4.2)

–

4 (4.6)

–

 pCCA

50 (34.7)

–

23 (26.4)

–

 eCCA

88 (61.1)

–

60 (69.0)

–

TNM stage, n (%)

 I

25 (17.4)

–

9 (10.3)

–

 II

63 (43.7)

–

16 (18.4)

–

 III

22 (15.3)

–

29 (33.3)

–

 IV

8 (5.6)

–

20 (23.0)

–

 N

26 (18.0)

–

13 (14.9)

–

Non-CCA group, n (%)

 CBD

–

113 (48.7)

–

116 (67.4)

 IBD

–

8 (3.4)

–

2 (1.2)

 CBD and IBD

–

26 (11.2)

–

5 (2.9)

 Pancreatic carcinoma

–

17 (7.3)

–

11 (6.4)

 Pancreatic duct stones

–

14 (6.0)

–

8 (4.7)

 Duodenal papilla carcinoma

–

4 (1.8)

–

2 (1.2)

 Cholangitic stenosis

–

12 (5.2)

–

7 (4.1)

 Cholecystolithiasis

–

26 (11.2)

–

15 (8.7)

 Gallbladder polyps

–

6 (2.6)

–

3 (1.7)

 Choledochal cyst

–

6 (2.6)

–

3 (1.7)

TBIL (μmol/L), n (%)

 ≥ 23

128 (88.9)

131 (56.5)

72 (82.8)

101 (58.7)

 < 23

16 (11.1)

101 (43.5)

15 (17.2)

71 (41.3)

GGT (U/L), n (%)

 ≥ 60

136 (94.4)

166 (71.6)

82 (94.3)

110 (64.0)

 < 60

8 (5.6)

66 (28.4)

5 (5.7)

62 (36.0)

TBA (μmol/L), n (%)

 ≥ 10

114 (79.2)

96 (41.4)

62 (71.3)

69 (40.1)

 < 10

30 (20.8)

136 (58.6)

25 (28.7)

103 (59.9)

CA19-9 (U/mL), n (%)

 ≥ 34

117 (81.3)

73 (31.5)

75 (86.2)

64 (37.2)

 < 34

27 (18.7)

159 (68.5)

12 (13.8)

108 (62.8)